MX2010009628A - Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos. - Google Patents

Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.

Info

Publication number
MX2010009628A
MX2010009628A MX2010009628A MX2010009628A MX2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A MX 2010009628 A MX2010009628 A MX 2010009628A
Authority
MX
Mexico
Prior art keywords
infective
liquid formulations
stable liquid
dosing regimens
adjusted
Prior art date
Application number
MX2010009628A
Other languages
English (en)
Inventor
Gary Liversidge
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Publication of MX2010009628A publication Critical patent/MX2010009628A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18Testing for antimicrobial activity of a material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proveen métodos para determinar un régimen de dosificación ajustado a la resistencia, de un agente antiinfeccioso para el tratamiento de una infección de un mamífero por un organismo infeccioso resistente, en donde se conoce un régimen de dosificación efectivo del agente antiinfeccioso para el tratamiento de una infección del mamífero por una cepa susceptible del organismo infeccioso; se proveen también métodos de tratamiento de una infección bacteriana resistente a cefepima en un paciente.
MX2010009628A 2008-03-04 2009-03-03 Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos. MX2010009628A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3359808P 2008-03-04 2008-03-04
PCT/US2009/035794 WO2009111422A2 (en) 2008-03-04 2009-03-03 Stable liquid formulations of anti-infective agents and adjusted anti-infective agent dosing regimens

Publications (1)

Publication Number Publication Date
MX2010009628A true MX2010009628A (es) 2010-09-28

Family

ID=41054292

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009628A MX2010009628A (es) 2008-03-04 2009-03-03 Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.

Country Status (12)

Country Link
US (2) US20090227554A1 (es)
EP (1) EP2257159A4 (es)
JP (1) JP2011514902A (es)
KR (1) KR20100137439A (es)
AU (1) AU2009222020A1 (es)
CA (1) CA2713989A1 (es)
IL (1) IL207968A0 (es)
MX (1) MX2010009628A (es)
NO (1) NO20101375L (es)
TW (1) TW200940552A (es)
WO (1) WO2009111422A2 (es)
ZA (1) ZA201005495B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9120795B2 (en) 2013-03-14 2015-09-01 Cubist Pharmaceuticals, Inc. Crystalline form of a β-lactamase inhibitor
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
MX2020004205A (es) * 2013-03-15 2021-11-16 Merck Sharp & Dohme Llc Composiciones antibioticas de ceftolozano.
US20140274991A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9120796B2 (en) 2013-10-02 2015-09-01 Cubist Pharmaceuticals, Inc. B-lactamase inhibitor picoline salt
US20180064723A1 (en) * 2016-03-31 2018-03-08 Wockhardt Limited Antibacterial compositions and methods
MX2017013434A (es) * 2016-03-31 2018-01-30 Wockhardt Ltd Composiciones antibacterianas.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1115417B1 (en) * 1998-09-25 2006-04-05 Cubist Pharmaceuticals, Inc. Use of daptomycin
JP2002543434A (ja) * 1999-04-29 2002-12-17 デイド マイクロスキャン インコーポレーテッド 迅速な抗菌物質感受性アッセイと微生物同定を組み合わせたシステム
US6884791B2 (en) * 1999-07-06 2005-04-26 Methylgene, Inc. Inhibitors of β-lactamase
US6482982B1 (en) * 2001-03-09 2002-11-19 University Of Sciences Of Philadelphia Halogenated antituberculosis agents
WO2004043335A2 (en) * 2001-09-13 2004-05-27 Genesoft, Inc. Methods of treating infection by drug resistant bacteria
US7378408B2 (en) * 2001-11-30 2008-05-27 Pfizer Inc. Methods of treatment and formulations of cephalosporin
US20030152515A1 (en) * 2002-02-06 2003-08-14 Ren-Jin Lee Method for estimating effective regimens and patient survival rates of antibiotic treatments for fatal infectious diseases
AU2003242404A1 (en) * 2002-06-13 2003-12-31 Hououdou Co., Ltd. Antibacterial agent and antibacterial composition
AU2003241675A1 (en) * 2002-06-21 2004-01-06 Shionogi And Co., Ltd. Medicinal cephem compound composition for injection
US7244712B2 (en) * 2003-03-14 2007-07-17 President And Fellows Of Harvard College Aminoglycoside antibiotics and methods of using same
US20060018966A1 (en) * 2003-07-22 2006-01-26 Lin Victor S Antimicrobial mesoporous silica nanoparticles
WO2005041978A1 (en) * 2003-10-21 2005-05-12 Johns Hopkins University Neuroprotection with beta-lactam compounds
WO2005089738A2 (en) * 2004-03-17 2005-09-29 Mpex Pharmaceuticals, Inc. Use and administration of bacterial efflux pump inhibitors
WO2005094800A2 (en) * 2004-03-31 2005-10-13 Lupin Ltd. A co-precipitated cefepime composition and process for preparation thereof
EP1656930A1 (en) * 2004-11-10 2006-05-17 Basilea Pharmaceutica AG Stabilized freeze-dried formulation for cephalosporin derivatives
US20070231335A1 (en) * 2005-07-20 2007-10-04 Bruce Beutler Compositions and methods for treating Gram positive bacterial infection in a mammalian subject
EP3718532A1 (en) * 2005-12-08 2020-10-07 Insmed Incorporated Lipid-based compositions of antiinfectives for treating pulmonary infections
AU2007229275B2 (en) * 2006-03-23 2013-02-07 Agriculture Victoria Services Pty Ltd Antimicrobial protein
US20090048160A1 (en) * 2007-08-17 2009-02-19 Bannerman Douglas D Antimicrobial activity of bovine bactericidal/permeability-increasing protein (BPI)-derived peptides against Gram-negative bacterial mastitis isolates
WO2009059379A1 (en) * 2007-11-07 2009-05-14 Dynamic Microbials Limited Antimicrobial compositions, formulations and uses thereof

Also Published As

Publication number Publication date
US20120115836A1 (en) 2012-05-10
EP2257159A4 (en) 2011-05-11
WO2009111422A3 (en) 2009-12-30
NO20101375L (no) 2010-10-04
KR20100137439A (ko) 2010-12-30
JP2011514902A (ja) 2011-05-12
IL207968A0 (en) 2010-12-30
WO2009111422A9 (en) 2010-04-15
CA2713989A1 (en) 2009-09-11
WO2009111422A2 (en) 2009-09-11
ZA201005495B (en) 2011-04-28
US20090227554A1 (en) 2009-09-10
TW200940552A (en) 2009-10-01
AU2009222020A1 (en) 2009-09-11
EP2257159A2 (en) 2010-12-08

Similar Documents

Publication Publication Date Title
MX2010009628A (es) Formulaciones liquidas estables de agentes antiinfecciosos, y regimenes de dosificacion ajustados de los agentes antiinfecciosos.
TN2012000335A1 (en) Antibody formulation and therapeutic regimens
MX2011007589A (es) Tratamiento de un cancer usando una combinacion de bendamustine y un anticuerpo anti-cd20.
MX2013010770A (es) Tratamiento de tumores solidos.
GEP201706786B (en) Methods and drug products for treating alzheimer's disease
MX2015007714A (es) Agente terapeutico de direccionamiento a glipicano 3 (gpc3) que es administrado a pacientes para quienes la terapia con agentes terapeuticos de direccionamiento a gpc3 es eficaz.
NZ717373A (en) The use of inhibitors of bruton’s tyrosine kinase (btk)
MX2013005564A (es) Medicamentos de canabinoides en bajas dosis.
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
NZ701715A (en) Means and methods for treating dlbcl
IN2012DN06309A (es)
MX338764B (es) Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion.
NZ591525A (en) Methods of treatment of complicated skin and skin structure infections using single doses of oritavancin
MX2009006574A (es) Tratamiento de cancer de pulmon.
WO2012174224A3 (en) Methods for administering nucleic acid-based therapeutics
ITFI20110166A1 (it) Nuovi fotosensibilizzanti ad uso terapeutico.
NO20091580L (no) Behandling av infant-hyperbilirubinemi ved anvendelse av lave doser stannsoporfin
RU2013104381A (ru) Лечение отслойки васкуляризированного пигментного эпителия терапевтическим средством против vegf
UA109944U (uk) Фармацевтична композиція для зниження рівня n-оксиду триметиламіну
MX358512B (es) Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
UA99163C2 (ru) Способ дозирования инъекционной формы палиперидона пальмитата продолжительного действия
TNSN06305A1 (en) Treatment regimen for camptothecin derivatives
UA35047U (ru) Способ проведения оздоровительной гимнастики
UA56131U (ru) Способ применения специфического иммуноглобулина против граммотрицательных бактерий для лечения сепсиса и тяжелых инфекций
UA58311U (ru) Способ дезинтоксикационной терапии при лечение собак с гнойными ранами

Legal Events

Date Code Title Description
FA Abandonment or withdrawal